哈药集团人民同泰医药股份有限公司关于购买公司董监高责任险的公告

Group 1 - The company plans to purchase directors, supervisors, and senior management liability insurance to enhance its risk management system and protect the rights of its executives and investors [1][2] - The insurance coverage limit is set at a maximum of RMB 100 million, with an annual premium not exceeding RMB 800,000 [1] - The insurance period is for 12 months, with the possibility of renewal or reinsurance [1] Group 2 - The decision to purchase the liability insurance was reviewed and approved in the company's board and supervisory meetings held on June 4, 2025 [2] - All directors and supervisors abstained from voting on the proposal, which was then submitted directly to the shareholders' meeting for approval [2] Group 3 - The company intends to cancel its supervisory board and amend its articles of association to improve governance and operational standards [4][5] - The supervisory board's powers will be transferred to the board's audit committee, and relevant internal regulations will be revised accordingly [6]